Key Takeaways
- • Private equity completed 75 healthcare transactions in December 2025, comprising 8 buyouts, 45 add-on acquisitions, and 22 growth/expansion investments, demonstrating sustained PE momentum in the sector following record 2025 performance.
- • Dental care (11 transactions), outpatient care (9 transactions), and medtech (7 transactions) dominated deal flow in December, reflecting PE's continued focus on fragmented healthcare subsectors amenable to consolidation.
- • Clinical trials emerged as a discrete investment focus area with at least three PE-backed deals in December, as firms target consolidation opportunities to extract returns through operational efficiencies without bearing drug development risk.
- • Healthcare private equity achieved record disclosed deal value exceeding $191 billion in 2025, surpassing the previous high of 2021, signaling robust institutional capital deployment despite ongoing stakeholder scrutiny regarding PE's healthcare footprint.
- • Perimeter Solutions announced acquisition of Medical Manufacturing Technologies for $685 million, closing in Q1 2026, exemplifying large-ticket medtech deal activity within the December cohort.
Summary
Private equity maintained aggressive healthcare acquisition velocity through December 2025, with the Private Equity Stakeholder Project documenting 75 transactions across multiple deal structures. The transaction mix—8 buyouts, 45 add-on acquisitions, and 22 growth investments—reflects PE's preference for bolt-on platforms and minority stakes alongside traditional leveraged buyouts. This deal composition aligns with broader 2025 PE performance, where the sector achieved record disclosed deal value exceeding $191 billion, surpassing 2021 highs.
Sector concentration remained pronounced. Dental care commanded 11 transactions, outpatient care generated 9 deals, and medtech attracted 7 transactions, together representing approximately 40% of December deal volume. This clustering mirrors historical PE targeting patterns documented in PESP's prior research, including the 2024 comprehensive review and earlier reports examining risks in dental consolidation under PE ownership. The prevalence of add-on acquisitions (60% of total activity) underscores PE's continuation of roll-up strategies within these fragmented subsectors, where consolidation economics enable margin expansion through operational leverage.
Clinical trials emerged as a discrete investment theme, with at least three PE transactions documented in December. PE investors are targeting clinical trial companies due to sector fragmentation and the profit extraction potential of consolidation. The investment thesis centers on operational efficiencies—accelerating timelines and reducing costs—while transferring drug development risk to sponsors. This approach enables PE to generate returns from platform scaling without bearing the existential risk of compound efficacy or regulatory approval.
The December data points reflect sustained institutional capital deployment into healthcare despite ongoing scrutiny regarding PE ownership models and patient impact. While supplemental market research indicates PE may face reimbursement headwinds and structural sector challenges in 2026, December 2025 activity demonstrates undiminished dealmaking momentum and capital availability. Mega-deals such as the Perimeter Solutions-Medical Manufacturing Technologies acquisition ($685 million) alongside numerous mid-market and lower-middle-market additions demonstrate diversified PE appetite across healthcare's value chain.
Sector concentration remained pronounced. Dental care commanded 11 transactions, outpatient care generated 9 deals, and medtech attracted 7 transactions, together representing approximately 40% of December deal volume. This clustering mirrors historical PE targeting patterns documented in PESP's prior research, including the 2024 comprehensive review and earlier reports examining risks in dental consolidation under PE ownership. The prevalence of add-on acquisitions (60% of total activity) underscores PE's continuation of roll-up strategies within these fragmented subsectors, where consolidation economics enable margin expansion through operational leverage.
Clinical trials emerged as a discrete investment theme, with at least three PE transactions documented in December. PE investors are targeting clinical trial companies due to sector fragmentation and the profit extraction potential of consolidation. The investment thesis centers on operational efficiencies—accelerating timelines and reducing costs—while transferring drug development risk to sponsors. This approach enables PE to generate returns from platform scaling without bearing the existential risk of compound efficacy or regulatory approval.
The December data points reflect sustained institutional capital deployment into healthcare despite ongoing scrutiny regarding PE ownership models and patient impact. While supplemental market research indicates PE may face reimbursement headwinds and structural sector challenges in 2026, December 2025 activity demonstrates undiminished dealmaking momentum and capital availability. Mega-deals such as the Perimeter Solutions-Medical Manufacturing Technologies acquisition ($685 million) alongside numerous mid-market and lower-middle-market additions demonstrate diversified PE appetite across healthcare's value chain.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.